SynthesisBMJ open2025
Prevalence and factors influencing fear of disease progression in stroke patients: a systematic review and meta-analysis with a focus on China.
Synthesis in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Illness perception and insomnia among patients with maintenance hemodialysis: a moderated mediation model of fear of progression and self-compassion.Renal failure · 2026Article
- Determinants and management approaches for fear of disease progression among stroke survivors.Medicine · 2026Article
- Fear of disease progression and its associated factors in patients with acute pancreatitis: a cross-sectional study.BMC gastroenterology · 2026Article
- Fear of disease progression among caregivers of outpatient children with perianal abscess: a cross-sectional survey.BMC pediatrics · 2026Article
- Prevalence and associated factors of fear of progression in patients with heart failure in China: a scoping review.Frontiers in psychiatry · 2026Review
- Fear of progression and association factors in stroke patients: a latent profile analysis.Frontiers in psychology · 2026Article
- Fear of progression profiles and their association with quality of life and depression in ischemic stroke survivors: a latent profile analysis.BMC psychiatry · 2025Article
- Development of a clinical prediction model for inflammatory biomarkers and enlarged basal ganglia perivascular spaces using SHAP analysis: feature selection and model interpretation.Frontiers in neurology · 2025Article
- Research on the construction strategy of China's rural emergency linkage system from the perspective of systems theory-based on the survey of six regions in China.Frontiers in public health · 2025Article
- Type D personality and fear of progression among patients with first-ever stroke: the serial mediation role of perceived social support and intolerance of uncertainty.Frontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo systematically estimate the prevalence and influencing factors of fear of disease progression (FoP) in patients who had a stroke, with a focus on China.
designSystematic review and meta-analysis of observational clinical studies. DATA SOURCES: Eight databases (China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database (VIP), CBM, Web of Science, PubMed, Cochrane Library, Embase) were searched from inception to March 2024, supplemented by manual reference screening. ELIGIBILITY CRITERIA: Cross-sectional studies reporting FoP incidence or influencing factors in Chinese stroke patients using the Fear of Progression Questionnaire-Short Form scale were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies, extracted data and assessed study quality using the Agency for Healthcare Research and Quality tool (score range: 0-11 points). Random-effects models were applied to address substantial heterogeneity. Stata 17.0 software was used for meta-analysis.
resultsA total of 20 studies (15 medium-quality, 5 high-quality) involving 7156 patients were included. The pooled incidence of FoP in Chinese stroke patients was 56% (95% CI=45% to 66%), derived from a random-effects model despite significant between-study heterogeneity (I²= 98.7%), with subgroup analyses and leave-one-out sensitivity analysis confirming result robustness. Subgroup analysis revealed that the incidence was highest in East China (70%, 95% CI=56% to 83%), followed by Central China (55%, 95% CI=36% to 73%) and North China (43%, 95% CI=38% to 47%). The incidence of FoP in haemorrhagic stroke (72%, 95% CI=49% to 95%) was higher than that in ischaemic stroke (45%, 95% CI=27% to 64%). The incidence of FoP after 2020 (59%, 95% CI=48% to 70%) was higher than that before 2020 (40%, 95% CI=32% to 47%). Meta-regression identified publication year (p=0.004) and research region (p=0.001) as key heterogeneity sources. The main influencing factors of FoP in Chinese stroke patients included age (OR=0.94, 95% CI=0.92 to 0.97, p<0.05), education level (OR=0.71, 95% CI=0.67 to 0.76, p<0.05), economic income (OR=0.74, 95% CI=0.69 to 0.78, p<0.05), body mass index (OR=1.22, 95% CI=1.04 to 1.43, p<0.05), social support (OR=0.75, 95% CI=0.63 to 0.90, p<0.05), illness perception (OR=1.41, 95% CI=1.37 to 1.45, p<0.05) and family intimacy (OR=0.80, 95% CI=0.67 to 0.96, p<0.05). No significant publication bias was detected (Egger's p=0.052, Begg's p=0.444), though funnel plot asymmetry suggested potential heterogeneity effects.
conclusionThe incidence of FoP in Chinese stroke patients is high (56%), influenced by age, education level, economic income, body mass index, social support, illness perception and family intimacy. Despite high heterogeneity, sensitivity analyses confirmed result robustness. Clinical staff should prioritise psychological screening for FoP and implement targeted interventions, such as cognitive-behavioural therapy for negative illness perception, social support programmes for low-income patients and family-centred education for younger patients. PROSPERO REGISTRATION NUMBER: CRD42024522147.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.